First published 10/3/2026, 1:30:15 AM · Last updated 10/3/2026, 1:30:15 AM

MA11.03 Tifcemalimab Plus Toripalimab and Chemotherapy as a First-Line Therapy in ES-SCLC: A Phase Ib/II Study

Journal article reporting a Phase Ib/II study of tifcemalimab plus toripalimab with chemotherapy as first-line therapy in extensive-stage small cell lung cancer (ES-SCLC). Published by Elsevier BV on 2025-10-01.

Illustrative image: This woman is being treated with docetaxel for breast cancer. Cooling mitts and wine coolers are placed on her hands and feet to prevent deleterious effects on the nails. Similar strategies can be used to prevent hair loss. — Jenny Mealing/Wikimedia Commons, CC BY 2.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The source documents a clinical study of a combination immunotherapy and chemotherapy regimen for ES-SCLC.

Sources

MA11.03 Tifcemalimab Plus Toripalimab and Chemotherapy as a First-Line Therapy in ES-SCLC: A Phase Ib/II Study

Report an issue